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Background and objective: Spirometry values may be expressed as T-scores in standard 
deviation units relative to a reference in a young, normal population as an analogy to the T-score 
for bone mineral density. This study was performed to develop the spirometry T-score.
Methods: T-scores were calculated from lambda-mu-sigma-derived Z-scores using a young, 
normal age reference. Three outcomes of all-cause death, respiratory death, and COPD death 
were evaluated in 9,101 US subjects followed for 10 years; an outcome of COPD-related 
health care utilization (COPD utilization) was evaluated in 1,894 Korean subjects followed 
for 4 years.
Results: The probability of all-cause death appeared to remain nearly zero until -1 of forced 
expiratory volume in 1 second (FEV
1
) T-score but increased steeply where FEV
1
 T-score reached 
below -2.5. Survival curves for all-cause death, respiratory death, COPD death, and COPD 
utilization differed significantly among the groups when stratified by FEV
1
 T-score (P,0.001). 
The adjusted hazard ratios of the FEV
1
 T-score for the four outcomes were 0.54 (95% confi-
dence interval, 0.48–0.60), 0.43 (95% CI: 0.37–0.50), 0.30 (95% CI: 0.24–0.37), and 0.69 (95% 
CI: 0.59–0.81), respectively, adjusting for covariates (P,0.001).
Conclusion: The spirometry T-score could predict all-cause death, respiratory death, COPD 
death, and COPD utilization.
Keywords: spirometry, T-score, COPD
Introduction
Spirometry can indicate various lung diseases and help determine their treatment 
and prognosis.1 The role of spirometry values, including forced expiratory volume in 
1 second (FEV
1
) and the ratio of FEV
1
 to forced vital capacity (FEV
1
/FVC), is well 
established in the diagnosis, the classification of disease severity, and the prediction 
of mortality for patients with COPD.2
However, the method used to define the cut-off value of airflow limitation for the 
diagnosis of COPD has been debated by two groups. One group suggested that the 
cut-off value of airflow limitation be defined by a fixed ratio (FEV
1
/FVC ,0.70 or/and 
FEV
1
 ,80% of predicted value),3 while the other group suggested that the cut-off value 
of airflow limitation by the lower limit of normal (FEV
1
/FVC or/and FEV
1 
less than the 
bottom 5% percentile of normal reference value) which has the same meaning as “the 
Z-score of FEV
1
/FVC or/and FEV
1 
,-1.64”.4 In addition to both of these suggestions, 
there is a third method used to define the cut-off value of airflow limitation, a spirometry 
T-score. Similar to defining the T-score of bone mineral density, spirometry T-score 
can be defined by the spirometry values corrected with the young age where the lung 
function is at peak. Older subjects are more vulnerable to, and have poorer outcomes 
due to respiratory diseases even though they may have the same spirometry values 
that are expressed in spirometry Z-score.5,6 In the present study, we hypothesized that 
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spirometry T-score may better predict the four outcomes of 
all-cause death, respiratory death, COPD death, and COPD-
related health care utilization (COPD utilization).
In this study, we developed the spirometry T-score. 
In addition, we compared the three methods of the fixed ratio, 
the spirometry Z-score, and T-score to answer the question 
as to which method has the best prediction performance for 
the four outcomes.
Methods
Overview
We performed this study using representative samples of the 
two general populations, the US and Korean. In relation to 
the spirometry values, the three outcomes of all-cause death, 
respiratory death, and COPD death were evaluated in 9,101 
subjects followed for 10 years in the Third National Health and 
Nutrition Examination Survey (US NHANES III). The fourth 
outcome of COPD utilization was evaluated in 1,894 subjects 
followed for 4 years in the Second Korean National Health and 
Nutritional Examination Survey (Korean NHANES II).
Calculation of spirometry Z-scores and 
T-scores
We developed the spirometry T-score by analogy to the 
bone mineral density T-score, which is expressed in standard 
deviation units relative to a reference in a young, normal 
population.7 However, in addition to age, spirometry values 
are also dependent on height. Therefore, taking into consid-
eration age and height for the development of a spirometry 
T-score, we used the lambda-mu-sigma (LMS) method, 
where spirometry values of median (mu), coefficient of varia-
tion (sigma), and skewness (lambda) were modeled.8
For the 9,101 US subjects, we calculated spirometry 
Z-scores and T-scores using look-up tables using a Microsoft 
Excel (Microsoft Corporation, Redmond, WA, USA) add-in 
the module, which has been developed by Stanojevic et al.9,10 
The young, normal reference for FEV
1 
and the FEV
1
/FVC 
ratio in the US population was the value at 23 years of age 
in males and 22 years of age in females, which are the ages 
when the median FEV
1
 is the highest.
As for the 1,894 Korean subjects, we calculated spirom-
etry Z-scores and T-scores using Korean reference equations 
developed with the LMS method (Table S1). The age of the 
young, normal reference for FEV
1
 and the FEV
1
/FVC ratio, 
was 19 years in males and 32 years in females for Koreans.
Us nhanes III data
We used anonymous, publically available data of 9,101 
subjects from the US NHANES III, which is a large, 
representative, stratified, random survey of the US population 
from 8 to 80 years of age.11 For this study, we used only 
the data of non-Hispanic white participants 17–80 years 
of age, who completed at least three acceptable spirometry 
maneuvers and also whose mortality status and height were 
available (Figure S1). The spirometry methods used in the US 
NHANES III have been described previously by Hankinson 
et al11 and in Centers for Disease Control and Prevention.12
all-cause death, respiratory death, and 
COPD death after 10 years of follow-up
The US NHANES III recorded all-cause deaths, which were 
ascertained from a public-use-linked mortality file that con-
tains information based on the National Death Index. Deaths 
from a respiratory cause were defined by the International 
Classification of Diseases (ICD) J10–J98 codes; deaths 
from COPD were defined the ICD codes of J40–J47 (but not 
including the asthma codes J45 or J46).
survival curves and hazard ratios of 
spirometry T-scores
The Kaplan–Meier survival curves for the groups strati-
fied by their spirometry T-scores were calculated with the 
log-rank test. The stratification of groups for the Kaplan–
Meier curves was determined arbitrarily, but the first level 
of cut-off was determined with FEV
1
 T-score of -2.5, 
below which the probability of all-cause death appeared to 
increase steeply (Figure 1). Hazard ratios of the spirometry 
T-score for death was calculated by Cox proportional hazard 
analysis with adjustment for age, sex, smoking history, and 
co-morbidity, including cancer, heart attack, heart failure, 
and diabetes.
COPD utilization during 4 years of 
follow-up
We linked the data of 1,894 subjects that were 40 years of age 
or older of the Korean NHANES II with the Korean National 
Health Insurance claims (Figure S2).13 In this study, we con-
sidered that health care utilization related to COPD occurred 
if a participant in KHANES II in 2001 used health care 
services including any procedures, tests, or treatments with 
a primary diagnosis of COPD between 2002 and 2005 based 
on data from Korean National Health Insurance claims.
statistical analyses
Statistical analyses were performed using SPSS software, 
version 18.0 (SPSS Inc., Chicago, IL, USA) and SAS 9.2 
(SAS Institute Inc., Cary, NC, USA). In addition, pROC 
in the R 2.15.2 software package for statistical computing 
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(https://www.r-project.org) was used for Delong’s method of 
comparison between areas under the receiver operating char-
acteristic (ROC) curves. To estimate Harrell’s concordance 
index (c-index) from each Cox proportional hazard model, the 
package ‘survival’ in R 2.15.2 was used. The 95% confidence 
intervals (CI) of the c-index were computed using bootstrap-
ping method (repetition 200 times) with R package “boot”. 
The peak ages of FEV
1
 were selected, where the medians of 
FEV
1 
were the maximum in the reference equation models of 
the LMS method. A P-value of less than 0.05 was considered 
statistically significant.
ethics statement
This study was approved by the institutional review board 
of the Asan Medical Center with the approval number 
of 2011-0907. The de-indentified secondary data of US 
NHANES III and Korean NHANES II are open to the public, 
and no US institutional review board approval is required.
Results
results from the analyses of the Us 
nhanes III
subject characteristics of the Us nhanes III
Among the 9,101 subjects, 51% were female. The mean 
age was 45 years and 52% had a smoking history (Table 1). 
Death from any cause occurred in 929 (10.2%) subjects 
during the 10 years of follow-up. Eighty-five subjects (0.9%) 
died of respiratory causes; 43 deaths (0.5%) were caused 
by COPD.
spirometry T-score for the prediction of all-cause 
death, respiratory, and COPD death
The probability of all-cause death, respiratory death, and 
COPD death during 10 years of follow-up appeared to 
increase steeply as FEV
1
 T-score decreased to negative values 
(Figure 1). The probability of all-cause death appeared to 
remain zero or nearly zero until an FEV
1 
T-score of approxi-
mately -1, and this increased slowly until reaching a score 
of approximately -2.5, after which the probability of death 
appeared to increase steeply (Figure 1A).
For the prediction of all-cause, respiratory, and COPD 
death, the prediction performance of the FEV
1
 T-score was 
higher than that of the FEV
1
 Z-score or the FEV
1
 percent of 
predicted value (P,0.001 for all comparisons; Figure 2A–C). 
As for the T-score of FEV
1
/FVC, the prediction performance 
was lower than FEV
1
 T-score (P,0.05 for all comparisons; 
Figure 2A–C and E–G).
The prediction performance of FEV
1
/FVC ratio itself was 
comparable to that of FEV
1
/FVC T-score for the prediction 
of respiratory death and COPD death (P=0.93 and 0.68, 
respectively; Figure 2F and G), and was even higher than 
that of FEV
1
/FVC T-score for the prediction of all-cause 
death (P,0.001 for both comparisons; Figure 2E). The 
prediction performance of the FEV
1
/FVC ratio was higher 
than that of FEV
1
/FVC Z-score for the prediction of all-cause 
death, respiratory death, COPD death, and COPD utilization 
(P,0.0001 for all comparisons; Figure 2E–G).
Cut-off values of spirometry T-scores for the 
prediction of all-cause death
The cut-off values of the FEV
1
 T-score that reached the 
maximum Youden index (sensitivity + specificity -1) for the 
prediction of all-cause death were -2.5 in males and -2.4 in 
females. The corresponding FEV
1
/FVC T-scores were -1.1 
in males and -1.6 in females. For the prediction of 10-year 
all-cause death, an FEV
1 
T-score of -2.5 had a sensitivity 
Table 1 Baseline characteristics of subjects included in this 
study
US subjects 
9,101 (100%)
Korean subjects 
1,894 (100%)
Number of subjects (%)
age (years)
17–39 4,092 (45.0%) n/a
40–64 3,247 (35.7%) 1,618 (85.4%)
$ 65 1,762 (19.4%) 276 (14.6%)
sex
Male 4,460 (49.0%) 924 (48.8%)
Female 4,641 (51.0%) 970 (51.2%)
smoking status
never smoker 4,395 (48.3%) 1,112* (59.9%)
Current or ex-smoker 4,706 (51.7%) 745 (40.1%)
Comorbidity
Cancer 676 (7.4%) n/a
heart attack 334 (3.7%) n/a
heart failure 223 (2.5%) n/a
Diabetes 605 (6.7%) n/a
hypertension 2,122 (23.5%) n/a
Mean ± standard deviation
spirometry values
FeV1 T-score -1.52±1.76 -0.83±1.26
FeV1 Z-score -0.35±1.24 0.21±1.10
FeV1 % of predicted 
value
89.0±16.8 95.0±14.6
FeV1/FVC T-score -0.89±1.03 -0.67±0.79
FeV1/FVC Z-score -0.21±0.97 -0.26±0.86
FeV1/FVC ratio 0.78±0.09 0.78±0.08
Notes: The Us subjects and Korean subjects were the participants of the Third 
national health and nutrition examination survey (Us nhanes III) and the second 
Korean national health and nutritional examination survey (Korean nhanes II), 
respectively. *The smoking history of 37 subjects was missing.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; n/a, not applicable.
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of 0.78 and a specificity of 0.78, which were higher than 
the indices calculated using the other criteria of abnormal 
spirometry (Table 2).
For the prediction of COPD death, the FEV
1
/FVC ratio 
with the cut-off value of 0.70 appeared to be comparable to 
FEV
1
 T-score with the cut-off value of -2.5 (Table 2).
survival curves and hazard ratios of the  
FeV1 T-score
Survival curves for all-cause death, respiratory death, and 
COPD death differed significantly among the groups when 
stratified into four groups (,-4.5, -4.5 to -3.6, -3.5 to -2.6, 
and $-2.5) by FEV
1
 T-score (P,0.001 for all log-rank tests; 
Figure 3A–C).
The adjusted hazard ratios of the FEV
1
 T-score for 
all-cause death, respiratory death, and COPD death were 
0.54 (95% CI: 0.48–0.60), 0.43 (95% CI: 0.37–0.50), and 
0.30 (95% CI: 0.24–0.37), respectively, adjusting for age, 
sex, smoking history, and co-morbidity in the US subjects 
(P,0.0001 for all Cox proportional hazard analyses).
results from the analyses of the Korean 
nhanes II
subject characteristics
Among 1,894 subjects from the Korean NHANES II data, 
51% were female. The mean age was 53 years, and 40% had 
a smoking history (Table 1). COPD utilization was observed 
for 156 (8.2%) subjects during 4 years of follow-up.
spirometry T-score for the prediction of COPD 
utilization
The probability of COPD utilization during 4 years of 
follow-up increased steeply as FEV
1
 T-score decreased to 
negative values (Figure 1I).
For the prediction of COPD utilization, the prediction 
performance of the FEV
1
 T-score was higher than that of the 
FEV
1
 Z-score or the FEV
1
 percent of predicted value (P,0.05 
for both comparisons; Figure 2D). As for the ratio of FEV
1
/
FVC, the prediction performance was higher than that of 
FEV
1
/FVC T-score or Z-score for the prediction of COPD 
utilization (P,0.05 for both comparisons; Figure 2H).
As for the prediction of COPD utilization, the cut-off 
value of FEV
1
 T-score was -1.5 and this reached the maxi-
mum of Youden index (Table S2).
survival curves and hazard ratios of the FeV1 T-score
Survival curves for COPD utilization differed significantly 
among the groups when stratified by FEV
1
 T-score (P,0.001 T
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spirometry T-score
for log-rank test; Figure 3D). The adjusted hazard ratio 
of the FEV
1
 T-score for COPD utilization was 0.69 (95% 
CI: 0.59–0.81) adjusting for age, sex, amount smoked, 
monthly income, presence of pulmonary symptoms, 
and physician-diagnosed COPD in the Korean subjects 
(P,0.001; Cox proportional hazard analysis).
Discussion
In this study, we developed a spirometry T-score that could 
predict all-cause death, respiratory death, and COPD death 
in the US population and COPD utilization in the Korean 
population. This study suggests that spirometry values might 
also be corrected in the same way as that of the diagnosis of 
osteoporosis for which a young, normal reference is used to 
determine T-scores of bone mineral density. The rationale 
for using T-score might be that the age-related vulnerability 
should be taken into account;5,6 the rationale for Z-scores is 
that the age-related variability should be taken into account.
We found that the probability of all-cause death appeared 
to increase steeply when the FEV
1 
T-score decreased below 
approximately -2.5 (Figure 1A). We also found that the 
optimal cut-off values of the FEV
1
 T-score for the predic-
tion of all-cause death were -2.5 in males and -2.4 in 
females, where the Youden index reached the maximum 
value. However, which cut-off value of spirometry should 
be chosen might be dependent on the outcome. As for the 
outcome of COPD utilization, the cut-off value of -1.5 in 
FEV
1
 T-score was the value where Youden index was the 
maximum (Table S2).
We also found that the prediction performance of FEV
1
/
FVC ratio itself was comparable to, or even better than 
that of FEV
1
/FVC T-score, for the prediction of all-cause 
death, respiratory death, COPD death, and COPD utilization 
(Figure 2E−H). In addition, the criteria of abnormal spirome-
try by “FEV
1
/FVC ,0.70” were comparable to that by “FEV
1
 
T-score ,-2.5” for the prediction of COPD death (Table 2). 
Figure 3 Kaplan–Meier survival curves for all-cause death (A), respiratory death (B), and COPD death (C) and also for COPD-related health care utilization (D).
Notes: a total of 9,101 subjects in the Us (A–C) and 1,894 subjects in south Korea (D) were stratified by FEV1 T-score. all-cause death, respiratory death, COPD death, 
and COPD-related health care utilization differed significantly among the four groups (P,0.001 by the log-rank tests).
Abbreviation: FeV1, forced expiratory volume in 1 second.
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However, the prediction performance of FEV
1
/FVC Z-score 
did not appear to be as good as that of FEV
1
/FVC ratio itself 
or T-score. The prediction performance for COPD death had 
a sensitivity of 0.63 and a specificity of 0.93, with a Youden 
index of 0.56 given that the criterion of abnormal spirometry 
was an FEV
1
/FVC ratio less than the lower limit of normal, 
bottom 5% percentile (which has the same meaning as an 
FEV
1
/FVC Z-score less than -1.64) (Table 2). If the criterion 
FEV
1
/FVC ,0.70 was chosen, then the sensitivity would be 
0.79 and specificity 0.85, with a Youden index of 0.64. These 
results might support the definition of airflow limitation using 
the FEV
1
/FVC criterion of less than 0.70, suggested by the 
COPD clinical practice guidelines.14,15
The T-score of bone mineral density is known to reflect 
future fracture risk. A recent meta-analysis found that fracture 
risk increases by 1.5-fold to 2.6-fold for every unit decrease 
in standard deviation of mean bone mineral density.16 In 
our study, one standard deviation decrease in FEV
1
 T-score 
increased the risk of all-cause death by 1.9 times (the recipro-
cal of 0.54), respiratory death by 2.3 times (1/0.43), COPD 
death by 3.3 times (1/0.30), and COPD-related health care 
utilization by 1.4 times (1/0.69). Therefore, FEV
1
 T-scores 
might be comparable to T-scores of bone mineral density.
There are some limitations to discuss. First, determining 
cause of death is not easy or clear, so ICD disease coding 
might not be as accurate as assumed in this study. However, 
the large sample size of this study would probably over-
come a coding issue. In addition, ICD disease coding has 
already been validated in previous studies in both US and 
Korean subjects.13,17 Second, to apply these study results 
to COPD patients, post-bronchodilator spirometry may be 
needed, because the clinical practice guidelines of COPD 
management suggest post-bronchodilator spirometry for 
the diagnosis and classification of COPD. Unfortunately, 
post-bronchodilator spirometry data are not available for the 
general population in the US or in Korea. The importance of 
post-bronchodilator spirometry may be challenged, because 
the clinical significance of bronchodilator responsiveness is 
not universally accepted.18 Third, this study included only 
white US and Korean participants and therefore, general 
application to other ethnicities can be limited. For subjects of 
other ethnicities, a global lung function equation developed 
by Quanjer et al19 may be of assistance. Finally, although 
Youden index is used to determine which methods are supe-
rior to others, it is not always informative. The usefulness 
of Youden index, also the sensitivity and specificity, are 
mainly determined on the setting or the goal. For example, 
the FEV/FVC ratio below the LLN would be better than the 
fixed FEV/FVC ratio in a situation where a physician would 
be in the clinical context of selecting patients who are not 
at risk of COPD.
Compared with the conventional diagnostic criteria of 
COPD, FEV
1
 T-score appears to be superior in prediction 
performance of important outcomes. Therefore, with the 
superior prediction performance of spirometry T-score, 
should we use it in clinical practice? Without a consensus of 
experts or academic societies, we should be prudent to use it 
in clinical practice, because a vast majority of evidences have 
been built with the diagnostic criteria of FEV
1
/FVC with 
a cut-off of 0.70 in research of COPD. Because this study 
shows that the criteria FEV
1
/FVC of less than 0.70 works 
acceptably and because spirometry T-score seems to be too 
complicated to develop, we suggest that the conventional 
diagnostic criteria of FEV
1
/FVC, with a cut off of 0.70, be 
acceptable for the diagnosis of COPD in clinical practice.
Conclusion
Spirometry T-score with the age of young, normal reference 
could predict all-cause death, respiratory death, COPD death, 
and COPD utilization.
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Figure S1 Flow of subjects’ selection from the Us nhanes III.
Abbreviation: nhanes III, Third national health and nutrition examination survey.
Figure S2 Flow of subjects’ selection from the Korean nhanes II.
Abbreviation: nhanes II, second national health and nutritional examination 
survey.
Supplementary materials
Table S1 selection of “healthy” subjects for the development of spirometry reference values for Koreans
Reasons of exclusion Number of 
subjects excluded
Number of subjects 
who remained
Total 4,927*
history of smoking $5 packs over whole life 2,038 2,889
Physician diagnosis of respiratory diseases
asthma 111 2,778
COPD 10 2,768
lung cancer 0 2,768
Pulmonary tuberculosis 118 2,650
Bronchiectasis 14 2,636
respiratory symptoms or limitation
Wheezing during past year 132 2,504
Wheezing when exercise during past year 68 2,436
Phlegm more than 3 months during past year 3 2,433
Cough more than 3 months during past year 0 2,433
activity limitation d/t respiratory problem 6 2,427
Occupational exposure to
noxious chemicals 72 2,355
environmental pollutants 95 2,260
Missing values
height and weight 7 2,253
FeV1 1 2,252
#
Notes: *Total number of participants for spirometry. #Final number of subjects for the development of spirometric reference equations.
Abbreviations: FeV1, forced expiratory volume in 1 second; d/t, due to.
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Table S2 Various criteria of abnormal spirometry for the prediction of COPD-related health care utilization (COPD utilization)
Criteria* of abnormal spirometry COPD-related health care utilization in the Korean subjects
Sensitivity Specificity Youden index#
FeV1 T-score ,-1.5* 0.50 0.74 0.24
FeV1 Z-score ,-1.0* 0.31 0.90 0.20
FeV1 % of predicted value ,79 0.31 0.90 0.21
FeV1/FVC T-score ,-1.8* 0.24 0.92 0.16
FeV1/FVC Z-score ,-1.4* 0.21 0.92 0.12
FeV1/FVC ,0.71* 0.37 0.87 0.24
Notes: The sensitivity and specificity for the prediction of COPD utilization during 4 years of follow-up in the Korean subjects. *The cut-off values were chosen where their 
Youden indices were the maximum. #Defined as sensitivity + specificity -1.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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